Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

NCT06607458 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Metastatic Colorectal Cancer

Interventions

DRUG: Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab
DRUG: Trifluridine-tipiracil plus Bevacizumab Alone

Sponsor

Delcath Systems Inc.